Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Immunohistochemical properties of bone marrow mast cells in systemic mastocytosis: Evidence for expression of CD2, CD117/Kit, and bcl-x(L)
Autore:
Jordan, JH; Walchshofer, S; Jurecka, W; Mosberger, I; Sperr, WR; Wolff, K; Chott, A; Buhring, HJ; Lechner, K; Horny, HP; Valent, P;
Indirizzi:
Univ Vienna, Dept Internal Med 1, Div Hematol & Hemostaseol, A-1090 Vienna, Austria Univ Vienna Vienna Austria A-1090 & Hemostaseol, A-1090 Vienna, Austria Univ Vienna, Dept Dermatol, Div Gen Dermatol, A-1090 Vienna, Austria Univ Vienna Vienna Austria A-1090 v Gen Dermatol, A-1090 Vienna, Austria Univ Vienna, Dept Clin Pathol, A-1090 Vienna, Austria Univ Vienna ViennaAustria A-1090 pt Clin Pathol, A-1090 Vienna, Austria Univ Tubingen, Dept Internal Med 2, Tubingen, Germany Univ Tubingen Tubingen Germany , Dept Internal Med 2, Tubingen, Germany Univ Tubingen, Inst Pathol, Tubingen, Germany Univ Tubingen Tubingen Germany Tubingen, Inst Pathol, Tubingen, Germany
Titolo Testata:
HUMAN PATHOLOGY
fascicolo: 5, volume: 32, anno: 2001,
pagine: 545 - 552
SICI:
0046-8177(200105)32:5<545:IPOBMM>2.0.ZU;2-R
Fonte:
ISI
Lingua:
ENG
Soggetto:
ACUTE MYELOID-LEUKEMIA; PROTOONCOGENE C-KIT; IMMUNOPHENOTYPIC CHARACTERIZATION; MYELOPROLIFERATIVE DISORDERS; HEMATOLOGIC DISORDERS; CATALYTIC DOMAIN; TISSUE-SECTIONS; POINT MUTATION; DISEASE; CLASSIFICATION;
Keywords:
mast cells; CD2; bcl-x(L); mastocytosis; immunohistochemistry;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Clinical Medicine
Life Sciences
Citazioni:
48
Recensione:
Indirizzi per estratti:
Indirizzo: Valent, P Univ Vienna, Dept Internal Med 1, Div Hematol & Hemostaseol, Wahringer Gurtel 18-20, A-1090 Vienna, Austria Univ Vienna Wahringer Gurtel 18-20 Vienna Austria A-1090 ustria
Citazione:
J.H. Jordan et al., "Immunohistochemical properties of bone marrow mast cells in systemic mastocytosis: Evidence for expression of CD2, CD117/Kit, and bcl-x(L)", HUMAN PATH, 32(5), 2001, pp. 545-552

Abstract

In an attempt to identify novel diagnostic markers for mast fell (MC)-proliferative disorders, serial bone marrow (bm) sections of 22 patients with mastocytosis (systemic indolent mastocytosis, n = 19; mast cell leukemia [MCL], n = 1; isolated bm mastocytosis, n = 2) were analyzed by immunohistochemistry using antibodies against CD2, CD15, CD29, CD30, CD31, CD34, CD45, CD51, CD56, CD68R, CD117, HLA-DR, bcl-2, bcl-x(L), myeloperoxidase (MPO), andtryptase. Staining results revealed expression of bd-x,, CD68R, and tryptase in neoplastic MCs (focal dense infiltrates) in all patients. Mastocytosis infiltrates were also immunoreactive for CD45, CD117 (Kit), and HLA-DR Inmost cases, the CD2 antibody produced reactivity with bm MCs in mastocytosis, whereas in control cases (reactive bm, immunocytoma, myelodysplastic syndrome), MCs were consistently CD2 negative. Expression of bcl-2 was detectable in a subset of MCs in the patient with MCL, whereas no reactivity was seen in patients with SIM or bm mastocytosis. Mastocytosis infiltrates did not react with antibodies against CD15, CD30, CD31, CD34, or MPO. In summary, our data confirm the diagnostic value of staining for tryptase, Kit, andCD68R in mastocytosis. Apart from these, CD2 may be a novel useful marker because MCs in mastocytosis frequently express this antigen, whereas MCs inother pathologic conditions are CD2 negative. Copyright (C) 2001 by W.B. Saunders Company.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 20/09/20 alle ore 23:36:04